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42 Markov and 19 MC. Median time since publication was 6 years. Most models 
concerned Type 2 DM (57%) and prevention or disease-management programs 
(54%). In average, models had 11 states and 2.8 complications. MC were signiﬁ cantly 
more used than Markov when both type 1 and 2 DM and a prevention or disease 
management program were concerned. Models had, signiﬁ cantly, a higher number of 
states and complications. The choice of the model type was shown to be inﬂ uenced 
by the number of DM and of complications considered. The justiﬁ cation to perform 
a Monte-Carlo was more often documented than those to perform a Markov (74% 
vs. 38%). The model was considered accurate with the study question in respectively 
86% of Monte-Carlo and 64% of Markov. CONCLUSIONS: This study allowed to 
statistically identify factors inﬂ uencing the type of model used to simulate DM. It is 
an interesting tool for modelers in their decision process to build a model. Information 
such as data and time availability or ﬁ nancial context could not be collected.
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SIMPLIFICATION OF PATIENT LEVEL SIMULATIONS TO COHORT 
MODEL FOR SCENARIO ANALYSIS
de Nigris E, Graham Roberts GR
Double Helix Consulting Group, London, UK
OBJECTIVES: In the last 15 years, models built to appraise health technologies have 
grown in complexity to accurately reﬂ ect the natural history of disease and calculate 
costs and beneﬁ ts accordingly. The advantage of using patient level simulation models 
(PSM) over cohort models (CM) is that CM may become unwieldy with thousands 
of branches. This usually happens if the patient characteristics inﬂ uence the risks of 
complications and these vary over time, or if there are many comorbidities to take 
into account and the risk of each complication is time dependent. In this case, a typical 
Markov cohort may be unsuitable. However a PSM can take a long time to run in 
order to produce results. Aim of this research is to present a case study where a PSM 
is simpliﬁ ed with a Markov structure and to compare the results of the two models. 
METHODS: We describe how a PSM for diabetes may be adapted to a CM, stating 
all the limitations. RESULTS: Provided that the PSM gives similar answers to the CM, 
the CM may be used as a surrogate for conducting complex sensitivity analysis (e.g., 
3-way analysis or tornado diagrams). The advantage is that this model would produce 
results “instantaneously.” CONCLUSIONS: The adaptation of a PSM model to a 
cohort model may be a desirable feature if the model is required by a non technical 
audience. This is the case for “due diligence” models that are increasingly required by 
investors to assess the value of assets that a pharmaceutical company considers to buy 
or sell. Further research is needed to have a powerful test to assess whether the dif-
ference in results between a simpliﬁ ed CM model and the PSM are statistically 
signiﬁ cant. 
MUSCULAR-SKELETAL DISORDERS – Clinical Outcomes Studies
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HIGHER COMORBIDITIES IN PATIENTS WITH GOUT VS. WITHOUT 
GOUT IN THE US GENERAL POPULATION: THE NATIONAL HEALTH 
AND NUTRITION EXAMINATION SURVEY (NHANES) 2007–2008
Pandya BJ1, Zhu Y2, Choi H2
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of Medicine, Boston, MA, USA
OBJECTIVES: While the comorbidity burden of gout in the US has been considered 
substantial and may have been rising over the past decade, no contemporary national 
data are available. We estimated the prevalence of major comorbidities in patients 
with gout compared with those without gout based on a recent, nationally representa-
tive sample of US men and women (National Health and Nutrition Examination 
Survey [NHANES] 2007–2008). METHODS: Using data from 5707 participants in 
NHANES 2007–2008 (2797 men and 2910 women) aged 20 years and older, we 
determined the prevalence of major comorbidities among individuals with gout, 
including hypertension, renal impairment, nephrolithiasis, diabetes, myocardial infarc-
tion, heart failure, stroke, and obesity. We also compared the prevalence with those 
without gout using age- and sex-adjusted logistic regressions. Case deﬁ nitions of 
comorbidities were based on an afﬁ rmative answer to a question asking if a physician 
or a health professional had diagnosed the corresponding condition. RESULTS: 
Among US adults with gout, 74% had hypertension, 53% obesity, 26% diabetes, 24% 
nephrolithiasis, 14% myocardial infarction, 11% heart failure, 10% stroke, and 9% 
renal impairment (Table). Prevalence of these comorbidities among individuals with 
gout was substantially higher than among individuals without gout. Age- and sex-
adjusted odds ratios (95% conﬁ dence interval [CI]) were 4.19 (2.75–6.39) for hyper-
tension, 2.35 (1–55–3.57) for obesity, 2.36 (1.49–3.73) for diabetes, 2.10 (1.39–3.18) 
for nephrolithiasis, 2.37 (1.54–3.65) for myocardial infarction, 2.68 (1.88–3.83) for 
heart failure, 2.02 (0.98 to 4.19) for stroke, and 3.50 (2.05–5.98) for renal impair-
ment. CONCLUSIONS: These ﬁ ndings from the latest nationally representative 
sample of US adults in NHANES 2007–2008 conﬁ rm that the prevalence of comor-
bidities among individuals with gout is substantial and considerably higher than 
among individuals without gout.
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DISABILITY OUTCOMES AND DOSE ESCALATION IN RHEUMATOID 
ARTHRITIS PATIENTS TREATED WITH TUMOR NECROSIS FACTOR 
BLOCKERS: A COMPARATIVE EFFECTIVENESS ANALYSIS
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OBJECTIVES: Previous cohort studies using US commercial insurance claims of 
rheumatoid arthritis (RA) patients have observed higher dose escalation rates for 
patients treated with tumor necrosis factor-α (TNF) blockers inﬂ iximab (INF) or 
adalimumab (ADA) than for etanercept (ETN). However, such databases cannot be 
used to determine whether dose escalation is associated with improved clinical out-
comes. We compared functional disability and dosing history between patients treated 
with TNF blockers using data from a large, prospective observational registry (Arthri-
tis, Rheumatism, and Aging Medical Information System; ARAMIS) of RA patients 
in the US. METHODS: ARAMIS enrolled adult physician-diagnosed RA patients. 
Patients who met following inclusion criteria were selected: treated with a TNF 
blocker for ≥9 months; had no biologics 6 months before index TNF treatment; and 
reported a Health Assessment Questionnaire Disability Index (HAQ-DI) at index and 
9–15 months after index. Self-reported dosing information was validated by telephone 
follow-up, medical, billing, or retail pharmacy prescription records. Dose escalation 
was deﬁ ned as dosing above ﬁ rst ADA/ETN or third INF dose. Multivariate models 
compared HAQ-DI change and dose escalation rates, controlling for variables that 
differed among INF, ADA and ETN patients at index. RESULTS: Approximately 351 
patients (93 INF, 40 ADA, 218 ETN) met study criteria. Subjects were mostly female 
(83%), Caucasian (88%), and had mean disease duration of 18.9 years. HAQ-DI 
change scores at 9–15 months did not differ by treatment (−0.10, −0.08, and −0.12 
points for INF, ADA, and ETN, respectively; P = 0.52). Dose increases were observed 
in 1.4% of ETN patients, as compared with 10.8% of INF (P < 0.001) and 12.5% 
of ADA patients (P = 0.004, both vs. ETN). HAQ-DI change was associated with 
pre-index HAQ-DI score and disease duration (both P < 0.05). CONCLUSIONS: This 
study showed dose escalation in fewer ETN than INF or ADA patients, but similar 
improvements in functional disability.
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IMPROVEMENT IN EFFICACY AND SAFETY OUTCOMES AFTER 
CERVICAL ARTHROPLASTY VERSUS STANDARD ANTERIOR CERVICAL 
DISECTOMY AND FUSION (ACDF) SURGERIES: A META-ANALYSIS OF 
PUBLISHED RCTS
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BACKGROUND: Cervical arthroplasty has been used successfully worldwide for over 
a decade in patients with cervical degenerative disc disease (CDDD). Several RCTs have 
documented the clinical advantage of arthroplasty vs. fusion for this patient population. 
Synthesis of outcomes from published RCTs is needed to consolidate the evidence-base 
for arthroplasty in CDDD. OBJECTIVES: To examine current evidence of safety and 
efﬁ cacy in the use of arthroplasty to treat CDDD and conduct a pooled analysis of high 
level comparative outcomes for arthroplasty versus fusion. METHODS: A systematic 
search of the PubMed, EMBASE, MEDLINE, CRD York, and Cochrane Library data-
bases, plus hand searching of grey literature was undertaken in January 2010. RESULTS: 
A total of 554 non-duplicate citations were retrieved. Only three studies of arthroplasty 
versus fusion with 2 years follow-up met all inclusion criteria and were of reasonable 
quality (according to GRADE criteria) to pool. a meta-analysis was conducted using 
RevMan5 software (Cochrane 2008). Persons undergoing single-level arthroplasty had 
signiﬁ cantly improved neurological success (RR 1.14, 95% CI [1.07, 1.21] P < 0.0001), 
Neck Disability Index (NDI) success (RR 1.13, 95% CI [1.05, 1.22] P = 0.001) and 
overall success (RR 1.22 95% CI [1.12, 1.33], P < 0.00001) at 2 years post surgery 
compared to fusion. Secondary surgeries (any revision, removal, or re-operation of the 
implant or supplemental ﬁ xation) after 2 years were also signiﬁ cantly lower with 
arthroplasty (13/621) compared to fusion (39/592), [0.32 95% CI [0.17, 0.59) P = 
0.0003]. Total number of patients undergoing reoperations at adjacent levels was lower 
in arthroplasty-treated patients (9/621) vs. ACDF (17/592), however it was not statisti-
cally signiﬁ cant (P = 0.09). Given the small numbers of patients undergoing reoperations 
at adjacent levels, longer term results are needed to increase precision of this estimate. 
CONCLUSIONS: A formal pooled analysis of 2-year RCT data demonstrates clinically 
signiﬁ cant improvements in efﬁ cacy and safety outcomes in CDDD patients who have 
undergone arthroplasty versus standard fusion.
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OBJECTIVES: To determine in patients with RA the number needed to treat (NNT) 
to achieve minimum clinically important differences (MCIDs) in multiple patient 
13th Euro Abstracts A303
reported outcomes (PROs) simultaneously following treatment with certolizumab 
pegol (CZP) 200 mg + methotrexate (MTX), in the RAPID 1 and RAPID 2 trials. 
METHODS: The proportions of patients reporting improvements ≥MCID in RAPID 
1 (Week 24 and Week 52) and RAPID 2 (Week 24) were determined for the following 
PROs: arthritis pain (0–100 mm visual analogue scale [VAS], MCID ≥ 10 mm), fatigue 
(Fatigue Assessment Scale, 0–10 numeric rating scale, MCID ≥ 1 point), physical 
function (Health Assessment Questionnaire-Disability Index, MCID ≥ 0.22 points), 
patient’s global assessment of disease activity (PtGA, 0–100 mm VAS, MCID ≥ 
10 mm), and HRQoL (SF-36 physical and mental component summaries [PCS, MCS], 
MCID ≥ 2.5 points). NNT to achieve improvements ≥MCID in at least 1, 2, 3, 4, 5, 
or 6 out of the 6 considered PROs simultaneously with CZP + MTX compared with 
PBO + MTX were also calculated. RAPID 1: NCT00152386; RAPID 2: NCT00160602. 
RESULTS: The NNT to report clinically meaningful improvements in up to 5/6 PROs 
following CZP + MTX treatment was very low; approximately 2–3 additional patients 
after 24 weeks (RAPID 1 and RAPID 2). The NNT remained similar at 52 weeks 
(RAPID 1). The NNT to report improvements in all 6 PROs was 5 additional patients. 
In patients who achieved MCIDs in at least 5 of 6 PROs by Week 52, clinically 
meaningful improvements were more likely to be reported in pain, fatigue, physical 
function and PtGA than SF-36 PCS or particularly MCS. CONCLUSIONS: Patients 
with active RA report meaningful and broad relief in PROs following treatment with 
CZP. The low NNTs indicate that few patients need to be treated with CZP + MTX 
to report relief from the multiple burdens of RA.
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PRIMARY ANTI-TNF FAILURES EXPERIENCE SUPERIOR CLINICAL 
RESPONSES TO A SECOND ANTI-TNF AGENT THAN SECONDARY 
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OBJECTIVES: A Provincial prospective observational cohort study observes consecu-
tive Rheumatoid Arthritis (RA) patients starting anti-TNF therapy (inﬂ iximab, etan-
ercept or adalimumab). We aimed to assess the impact of switching anti-TNF agents 
at different time points. METHODS: Data in the registry is collected at baseline, 3 
months, and every 6 months thereafter up to 3 years on patients receiving anti-TNF 
agents. We grouped patients as inﬂ iximab or adalimumab starters, and etanercept 
starters. Health-related quality of life was measured with the EQ-5D and single index 
scores were calculated using US value sets. Clinical outcome measures assessed were 
the HAQ and DAS28 scores. We analyzed the mean EQ-5D index score, the HAQ 
score, and the DAS28 score over time within baseline starter groups according to the 
time of switch of treatment. RESULTS: From 1222 patients in the registry, 649 
patients had 27 months follow-up assessment and 76.7% remained on the ﬁ rst anti-
TNF. For these patients, signiﬁ cant improvement was observed by 3 months in the 
EQ-5D (mean change 0.296, P < 0.001), the HAQ (mean change −0.822, P < 0.001) 
and DAS28 (mean change −2.84 P < 0.001) that was sustained over the follow-up 
period. Those who switched at 3 months (primary failures) had signiﬁ cantly responded 
by the next measurement and the 27 months changes in outcomes were comparable 
to non-switchers (all P < 0.01). Patients who failed the ﬁ rst anti-TNF after the 3-month 
time point (secondary failures) obtained from 50% (HAQ) to 68% (EQ-5D) of the 
mean change compared to non-switchers (P < 0.05). Switching from Inﬂ iximab or 
adalimumab to etanercept or vice versa produced similar outcomes. CONCLUSIONS: 
The results show that primary failures to anti-TNF show similar responses to patients 
responding to their ﬁ rst anti-TNF agent. Secondary failures obtain about two-third of 
the outcomes compares to no-switchers and primary failures. Longer follow up is 
needed to see if the secondary failure patients can sustain the obtained 
improvement.
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OBJECTIVES: Rheumatoid arthritis (RA) is a chronic, progressive, disabling autoim-
mune disease. The ﬁ rst biologic drug (etanercept) for the treatment of RA was regis-
tered in 1998, the latest in 2009 (EMEA). Study design of randomized controlled trials 
(RCT) of RA has changed in the past years, specially in point of reducing the time on 
placebo. Our aim was to compare the efﬁ cacy, safety and tolerability of available 
biologic drugs and to review the challenges of comparing RA studies with different 
structures, taking the example of the lately registered drug certolizumab pegol. 
METHODS: Systematic literature search was performed (closed on 16.08.2009) for 
RCTs with minimum duration of 24 weeks, involving drugs that have been registered 
for the treatment of RA after traditional disease modifying drug failure. Improvement 
of symptoms by 20%, 50% and 70% (deﬁ ned by the American College of Rheumatol-
ogy, ACR), adverse events and withdrawals were considered as endpoints in the 
metaanalysis. RESULTS: Altogether 14 RCTs (adalimumab 3, certolizumab pegol 2, 
etanercept 2, inﬂ iximab 4, tocilizumab 2, golimumab 1) involving 6739 patients were 
selected for the analysis. Efﬁ cacy of certolizumab pegol was superior to other drugs 
at ACR20, 50 and 70 but heterogenity was observed at certain safety endpoints. 
Contrary to previous trials, patients on placebo not achieving ACR20 response at 
week 16 were withrawn in the certolizumab pegol studies. Thus patient number in 
the placebo group decreased dramatically for the remaining 8 weeks. To exclude this 
bias, we compared only the active arms and there was no signiﬁ cant difference in 
terms of safety and tolerability among the drugs. Analysis by patients years conﬁ rmed 
this ﬁ nding. CONCLUSIONS: Effectiveness and safety of recently registered biologic 
drugs in RA are similar to the previous agents. Differences in protocol of former and 
present RCTs should be carefully considered for the analysis.
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OBJECTIVES: Switching among tumor necrosis factor-α inhibitor (TNFi) agents or 
to another biologic is relatively common, but determinants of dose escalation are 
largely unknown. Among individuals who are escalating the dose from their ﬁ rst TNFi, 
we identiﬁ ed factors associated with the choice of dose escalation in a retrospective 
analysis of medical and pharmacy claims and eligibility data. METHODS: Eligible 
patients were ≥18 years of age, diagnosed with rheumatoid arthritis (RA, 2 diagnoses 
≥2 months apart) from January 2003–March 2008, had initiated a new TNFi prescrip-
tion after a 6-month biologic-free period and had at least 6 months of continuous 
enrollment. Kaplan-Meier (KM) analysis and Cox regression were used to analyze 
time to dose escalation. Multinomial logistic regression was used to determine factors 
affecting dose escalation. RESULTS: A total of 11,903 (6.9%) of 173,533 RA patients 
were identiﬁ ed. Among these patients, 16% (n = 1,903) after a mean of 261 days 
escalated their dose. Comorbidity scores, such as the severity index for rheumatoid 
arthritis (SIFRA) and Elixhauser, were higher for patients who escalated their dose. 
The likelihood of escalating the dose was increased by female sex, younger age, and 
baseline use of corticosteroids or cytotoxic agents. Baseline use of methotrexate raised 
the likelihood of dose escalation (relative risk ratio, 1.58). CONCLUSIONS: After 
initiating TNFi treatment, many RA patients failed to remain on therapy and escalated 
doses or switched to a second TNFi or another biologic ~1 year. Factors inﬂ uencing 
whether patients increased their dose included gender, age, and use of certain agents 
at initiation of the TNFi. a limitation of this study is that patients with <6 months of 
TNFi treatment were not included.
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OCCURRENCE OF SECUNDARY HIP AND FEMUR FRACTURES 
ACCORDING TO RISK FACTORS FOLLOW-UP 8 YEARS
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OBJECTIVES: The aim of this study is to evaluate the occurrences of secundary hip 
and femur fractures according to its different risk factors with follow up 8 years. 
METHODS: In this retrospective study the data derive from the ﬁ nancial database of 
the Hungarian National Health Insurance Fund Administration, based on the 10th 
revision of the International Classiﬁ cation of Diseases (ICD) with ICD code S7200. 
The patients included into the study had femur neck fracture and being discharged 
from the hospital after the primary treatment in 2000. The patients with polytrauma 
were excluded from the study. We evaluated data according to sex, age, type of 
fracture, type of surgery, local complications, type of residence. RESULTS: A total of 
3783 patients met selection criteria of primary femoral neck fracture. During the 
postoperative 8 years 347 patents (9,2%) had secondary hip and femur fractures. 
Average age of patient with primary hip fracture 78 years, with secundary hip fracture 
80,6 years. We demonstrated the following incidence rate of secundary hip fractures 
according to risk factors: Sex: female: 10,3%, male: 5,8%. Age groups: 60–69 y: 
5,3%, 70–79 y: 7,5%, 80–89 y: 12,4%, 90 y-: 14,1%. Type of fracture: lateral: 6,9%, 
medial 9,5%. Type of surgery: osteosynthesis: 8,5%, arthroplasty: 13,6%. Local 
complications: yes: 10,6% no: 9%. Type of residence: capital 11,5%, village: 7,9%, 
city: 10%, town: 8,2%. CONCLUSIONS: The secondary hip fracture rate increased 
with the age of patients. The secondary hip fracture rate was the highest in female, in 
patient with primary intracapsular femoral neck fracture, after arthroplasty, in patient 
with local complication, in patient with capital residence. Many other factors can 
inﬂ uence this secondary hip fractur, which will be analyzed in our further studies.
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TREND OF HIP FRACTURE INCIDENCE IN BELGIUM BETWEEN 2000 
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OBJECTIVES: The primary aim of this study was to assess the incidence of hip 
fractures in Belgium between 2000 and 2007 and to examine secular changes within 
this period. a secondary aim was to estimate the expected number of hip fractures in 
Belgium until 2050. METHODS: The incidence of hip fractures was determined using 
the national database of hospital bills, which fully cover the annual hospital stays in 
the whole of the country. Population data and projections were derived from ofﬁ cial 
sources. Logistic regression including year and age classes was performed for both 
